Suppr超能文献

转移性乳腺癌女性患者使用CDK4和6抑制剂的治疗体验:一项定性研究

Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.

作者信息

Stephenson Judith J, Gable Jonathon Colby, Zincavage Rebekah, Price Gregory L, Churchill Collin, Zhu Emily, Stenger Keri, Singhal Mukul, Nepal Bal, Grabner Michael, Fisch Michael J, Debono David, Geschwender Amy R, Cuyun Carter Gebra

机构信息

HealthCore, Inc., Wilmington, DE, USA.

Eli Lilly and Company, Indianapolis, IN, USA.

出版信息

Patient Prefer Adherence. 2021 Nov 3;15:2417-2429. doi: 10.2147/PPA.S319239. eCollection 2021.

Abstract

PURPOSE

To describe patients' perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i's) to treat metastatic breast cancer (MBC).

METHODS

This qualitative study consisted of 60-minute semi-structured telephone interviews with patients with MBC in the US who were either current or recent CDK4&6i users, identified from administrative claims of survey-eligible commercial and Medicare Advantage patients in the HealthCore Integrated Research Database between November 1, 2018 and November 1, 2019. Patients were recruited by email and/or mailed letter. The 60-minute telephone interviews were conducted by a trained facilitator using a study-developed interview discussion guide that included topics impacting treatment choice and adherence/persistence. Interviews were audio-recorded, transcribed, and thematically analyzed.

RESULTS

All 462 eligible patients were sent a recruitment email and/or letter to which 36 patients responded, consented to participate, and met study inclusion criteria; 25 patients scheduled interviews, and 24 completed them. Study participants were predominately white, non-Hispanic (96%) with a mean age of 59.5 years. Participants reported a largely positive experience and mentioned very few adherence/persistence issues. They further reported appreciating the ease and convenience of oral oncolytics, coped with side effects, had strong medical and social support, and experienced few cost issues.

CONCLUSION

The few adherence/persistence issues reported by participants contrasts with other findings of suboptimal oral oncolytic use. Interview themes indicated several factors that likely contributed to the lack of adherence/persistence issues: trusted relationship with oncologist, belief in importance of medication, positive medication views, strong medical and social support, and minimal personal drug cost. Future research should focus on whether and how much these factors impact adherence/persistence in more diverse populations. If adherence/persistence issues are identified in these populations, then it would be appropriate to study the development of interventions that target factors associated with better adherence/persistence.

摘要

目的

描述患者对于使用细胞周期蛋白依赖性激酶4和6抑制剂(CDK4&6i)治疗转移性乳腺癌(MBC)的看法以及在坚持/持续使用该药物方面可能面临的挑战和障碍。

方法

这项定性研究包括对美国MBC患者进行60分钟的半结构化电话访谈,这些患者为当前或近期使用CDK4&6i的用户,从2018年11月1日至2019年11月1日HealthCore综合研究数据库中符合调查条件的商业保险和医疗保险优势患者的行政索赔记录中识别出来。通过电子邮件和/或信件招募患者。60分钟的电话访谈由一名经过培训的主持人进行,使用研究制定的访谈讨论指南,其中包括影响治疗选择和坚持/持续用药的主题。访谈进行录音、转录并进行主题分析。

结果

向所有462名符合条件的患者发送了招募电子邮件和/或信件,其中36名患者回复、同意参与并符合研究纳入标准;25名患者安排了访谈,24名完成了访谈。研究参与者主要是白人、非西班牙裔(96%),平均年龄为59.5岁。参与者报告的体验大多是积极的,提到的坚持/持续用药问题很少。他们还表示赞赏口服肿瘤药物的易用性和便利性,能应对副作用,有强大的医疗和社会支持,且很少遇到费用问题。

结论

参与者报告的少数坚持/持续用药问题与其他关于口服肿瘤药物使用不理想的研究结果形成对比。访谈主题表明了几个可能导致缺乏坚持/持续用药问题的因素:与肿瘤学家的信任关系、对药物重要性的信念、对药物的积极看法、强大的医疗和社会支持以及个人药物成本最低。未来的研究应关注这些因素是否以及在多大程度上影响更多样化人群的坚持/持续用药情况。如果在这些人群中发现了坚持/持续用药问题,那么研究针对与更好的坚持/持续用药相关因素开发干预措施将是合适的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5107/8573215/c08b9d8093cd/PPA-15-2417-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验